ProfileGDS5678 / 1418494_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 41% 42% 42% 41% 40% 39% 42% 43% 52% 41% 42% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9758641
GSM967853U87-EV human glioblastoma xenograft - Control 22.9407341
GSM967854U87-EV human glioblastoma xenograft - Control 32.9604442
GSM967855U87-EV human glioblastoma xenograft - Control 42.9165142
GSM967856U87-EV human glioblastoma xenograft - Control 52.8918241
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0042640
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9530839
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9678942
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9760343
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2527952
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9392141
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9357242
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9438741
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9438241